{"id":4883,"date":"2018-06-01T09:22:56","date_gmt":"2018-06-01T08:22:56","guid":{"rendered":"http:\/\/www.library.sath.nhs.uk\/research\/?p=4883"},"modified":"2019-04-23T12:34:24","modified_gmt":"2019-04-23T11:34:24","slug":"real-world-efficacy-of-12-weeks-sofosbuvir-daclastivir-with-ribavirin-among-cirrhotic-pre-and-post-transplant-genotype-3-2017","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2018\/06\/01\/real-world-efficacy-of-12-weeks-sofosbuvir-daclastivir-with-ribavirin-among-cirrhotic-pre-and-post-transplant-genotype-3-2017\/","title":{"rendered":"Real world efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin among cirrhotic pre and post-transplant genotype 3 (2017)"},"content":{"rendered":"<p><strong>Type of publication:<\/strong><br \/>\nConference abstract<\/p>\n<p><strong>Author(s):<\/strong><br \/>\nSchmidt-Martin D.; Bufton S.; Haydon G.H.; Mutimer D.; Elsharkawy A.M.; Roberts M.; *Rye K.; Singhal S.; Eldred S.; Perry I.; Corbett C.; Unitt E.; Wood V.; Dillon H.<\/p>\n<p><strong>Citation:<\/strong><br \/>\nJournal of Hepatology; 2017; vol. 66 (no. 1)<\/p>\n<p><strong>Abstract:<\/strong><br \/>\nBackground and Aims: Current EASL guidelines recommend combined Sofosbuvir and Daclatasvir with Ribavirin (SOF + DCV + RBV) for 24 weeks in compensated\/decompensated cirrhosis for genotype 3 patients. We investigated response to 12weeks treatment in a large cohort of pre and post-transplant predominantly compensated cirrhotic genotype 3 patients. Methods: All patients who received a single dose and treated in 8 treatment centres within our hospital network included. SVR12 rates for all patients who started treatment are reported on an intention to treat (ITT) basis and we include a modified intention to treat (mITT) analysis excluding non virological failures. Results: 156 patients ((M:F) 109:47) mean age 51.5 were\u00a0commenced on treatment. The overall SVR12 rate was 88.5% (138\/156) (ITT) and 95.8% (138\/144) (mITT). 2 patients stopped treatment without side effects. Five patients did not attend for confirmation of SVR12, three patients died on treatment (2 due to cardiac arrest, 1 due to sepsis) and a further patient died following\u00a0completion of treatment prior to SVR12 (hepatocellular carcinoma). mITT SVR12 for patients with compensated and decompensated cirrhosis (Child Pugh B\/C) were 96.7% (116\/120) and 82% (23\/28)respectively. 96.4% (80\/83) of patients with previous exposure to interferon and ribavirin achieved SVR12. All patients with HIV co infection achieved SVR (n = 8). 89% of liver transplant patients achieved SVR. 18%(5\/28) of\u00a0the decompensated cohort (Child Pugh B\/C) had died within 2 years of commencing treatment. Conclusions: SOF + DCV + RBV for 12 weeks achieved real world SVR12 rates comparable with 24 weeks treatment in cirrhotic genotype 3 patients or 12 weeks sofosbuvir\/velpastasvir. This is the largest reported cohort of posttransplant genotype 3 patients with advanced fibrosis. Our data suggests 12 weeks treatment for all cirrhotic patients may be considered regardless of previous interferon and ribavirin exposure (Table presented).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Conference abstract Author(s): Schmidt-Martin D.; Bufton S.; Haydon G.H.; Mutimer D.; Elsharkawy A.M.; Roberts M.; *Rye K.; Singhal S.; Eldred S.; Perry I.; Corbett C.; Unitt E.; Wood V.; Dillon H. Citation: Journal of Hepatology; 2017; vol.<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2018\/06\/01\/real-world-efficacy-of-12-weeks-sofosbuvir-daclastivir-with-ribavirin-among-cirrhotic-pre-and-post-transplant-genotype-3-2017\/\">Read more <span class=\"screen-reader-text\">Real world efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin among cirrhotic pre and post-transplant genotype 3 (2017)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[677,780,779],"class_list":["post-4883","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-677","tag-cirrhosis","tag-hepatitis-c"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=4883"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4883\/revisions"}],"predecessor-version":[{"id":5329,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/4883\/revisions\/5329"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=4883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=4883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=4883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}